HomeBiotechnology

Biotechnology

Latest news, analysis, and insights from ASX biotechnology companies

EMVision Medical Devices Awarded $3m Grant to Expand Brain Scanner into Trauma Care
Lead storyBiotechnology

EMVision Medical Devices Awarded $3m Grant to Expand Brain Scanner into Trauma Care

EMVision wins $3m federal grant to develop and test its portable brain scanner for traumatic brain injury, expanding beyond stroke detection.

Latest Stories — SECTOR DESK

Advertisement
Mayne Pharma Agrees to $604m Takeover Proposal from Gedeon Richter
Biotechnology

Mayne Pharma Agrees to $604m Takeover Proposal from Gedeon Richter

Mayne Pharma agrees to Gedeon Richter’s $604m cash takeover at $6.40 a share—a 99.4% premium—with unanimous board backing.

Imricor Medical Systems Adds First US Hospital Customers for iMR Procedures
Biotechnology

Imricor Medical Systems Adds First US Hospital Customers for iMR Procedures

Imricor Medical Systems signs its first two US hospital customers for iMR cardiac procedures, marking a key step in commercialisation.

Artrya Signs Five-Year Deal with HonorHealth to Expand US Cardiac Imaging Reach
Biotechnology

Artrya Signs Five-Year Deal with HonorHealth to Expand US Cardiac Imaging Reach

Artrya signs a five-year, US$0.5m minimum deal with HonorHealth, expanding its Salix cardiac imaging software across nine Arizona hospitals.

Clarity Pharmaceuticals Granted Breakthrough Therapy Designation for Prostate Cancer Copper Theranostic
Biotechnology

Clarity Pharmaceuticals Granted Breakthrough Therapy Designation for Prostate Cancer Copper Theranostic

Clarity Pharmaceuticals wins FDA breakthrough status for prostate cancer PET agent 64Cu-SAR-bisPSMA, a major milestone for its copper theranostic program.

BlinkLab Reports Positive Results from Smartphone-Based Study into Genetic Autism
Biotechnology

BlinkLab Reports Positive Results from Smartphone-Based Study into Genetic Autism

BlinkLab reports positive SHANK2 autism study results, with its smartphone test detecting significant differences in brain and sensorimotor measures.

EVE Health Group Signs Australian Pharmacy Deal for Men's Health Range
Biotechnology

EVE Health Group Signs Australian Pharmacy Deal for Men's Health Range

EVE Health signs Australian pharmacy deal for its men’s health range, retaining 75% of distributable profit in a capital-light route to market.

Immutep Reports Exposure-Dependent Inhibition of T-Cell-Driven Responses in IMP761 Phase I Study
Biotechnology

Immutep Reports Exposure-Dependent Inhibition of T-Cell-Driven Responses in IMP761 Phase I Study

Immutep’s IMP761 showed significant, exposure-dependent suppression of T-cell responses in Phase I, with no serious or severe adverse events.

Mayne Pharma Sells International Operations for $55.5m to Focus on US Business
Biotechnology

Mayne Pharma Sells International Operations for $55.5m to Focus on US Business

Mayne Pharma sells international operations for $55.5m, sharpening its focus on US Women’s Health, Dermatology and DistributeRx growth.